Drug Patents owned by Leo Labs

1. List of Picato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833428 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8716271 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US9820959 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8735375 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US9861603 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8372828 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8536163 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8372827 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8377919 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US9833429 LEO LABS Therapeutic compositions
Dec, 2026

(3 years from now)

US8278292 LEO LABS Therapeutic compositions
Jul, 2027

(4 years from now)

US9789078 LEO LABS Method of topically treating actinic keratosis with ingenol mebutate cycle therapy
May, 2033

(10 years from now)

Drugs and Companies using INGENOL MEBUTATE ingredient

Market Authorisation Date: 23 January, 2012

Treatment: Use of ingenol mebutate to treat actinic keratosis; Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate

Dosage: GEL;TOPICAL

How can I launch a generic of PICATO before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in